Neurocrine Biosciences | Bénéfice Avant Impôts

Prix De L'Action
141.20
Variation Quotidienne
3.27 2.37%
Mensuellement
0.41%
Annuel
15.15%
Q1 Prévisions
136.87




Bénéfice Avant Impôts Changement Date
AbbVie USD 4.38B 1.92B 2025-09
Acadia Pharmaceuticals USD 44.6M 4.38M 2025-09
Agios Pharmaceuticals USD -103.43M 8.59M 2025-09
ALKERMES USD 100.74M 4.1M 2025-09
Alnylam Pharmaceuticals USD 238.97M 274.33M 2025-09
Amgen USD 3.92B 2.35B 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Cytokinetics USD -306.18M 171.81M 2025-09
Dynavax Technologies USD 28.42M 7.2M 2025-09
Exelixis USD 252.41M 22M 2025-09
Gilead Sciences USD 2.43B 780M 2025-06
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Incyte USD 482.31M 75.7M 2025-09
Ionis Pharmaceuticals USD -129M 253M 2025-09
Neurocrine Biosciences USD 291.8M 132.3M 2025-09
Pfizer USD 3.33B 290M 2025-09
Prothena USD -36.91M 44.05M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Repligen USD 17.11M 10.25M 2025-09
Sarepta Therapeutics USD -194.05M 347.69M 2025-09
Teva Pharmaceutical Industries USD 91M 555M 2025-12
Ultragenyx Pharmaceutical USD -179.54M 65.54M 2025-09
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09


Neurocrine Biosciences Bénéfice Avant Impôts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.